GRAIL
IPOMulti-cancer early detection
Public · Menlo Park, United States · Founded 2015 · $835.0M raised
- Headquarters
- Menlo Park, California
- Employees
- 1001–5000
- Founded
- 2015
- Business Model
- B2B
- Website
- grail.com
- Total Funding
- $835.0M
- Last Round
- $110.0M Corporate RoundJun 2026
- Rounds
- 6
- Type
- Public
About
GRAIL is a healthcare company focused on multi-cancer early detection (MCED) through its Galleri blood test, leveraging next-generation sequencing, machine learning, and large-scale clinical studies. Headquartered in Menlo Park, it aims to change the cancer trajectory by detecting deadly cancers early when more treatable.
Summary
GRAIL is a Biotech company based in Menlo Park, United States, founded in 2015. It has raised $835.0M in total across 6 rounds, most recently a $110.0M Corporate Round round in Jun 2026. Investors include Samsung C&T Corporation, Illumina Ventures and Samsung Electronics.
Tech & App Stack
7 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2026
Sign up to see all 7 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Novel DNA sequencing architecture to scale the ultra low cost whole genome
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company